Zydus Lifesciences Limited has announced the successful completion of its investment in Zydus Sunshine Lifesciences (Private) Limited. This transaction, which involved subscribing to 50% of the total paid-up equity share capital, establishes Zydus Sunshine as a 50:50 joint venture between Zydus and Sunshine Healthcare Lanka Limited. The completion date was November 11, 2026, following an initial announcement on June 26, 2026, and a subsequent extension of the closing date.
Joint Venture Finalized
Zydus Lifesciences Limited has officially informed stakeholders that the transaction involving the subscription of equity shares and the formation of a joint venture with Zydus Sunshine Lifesciences (Private) Limited has been successfully completed. The company executed a Share Subscription and Shareholders’ Agreement (SSSHA) with Sunshine Healthcare Lanka Limited, agreeing to subscribe to 50% of the total paid-up equity share capital of Zydus Sunshine.
Strategic Partnership Established
Following the subscription of shares, Zydus Sunshine has now become a 50:50 joint venture between Zydus Lifesciences and Sunshine Healthcare Lanka. This strategic partnership was originally expected to be finalized within 90 working days from the initial announcement on June 26, 2026. The closing date was subsequently extended to December 2026, and the transaction was ultimately completed on November 11, 2026.
The delay in sending the official intimation was attributed to office holidays during the festive season. This development marks a significant step in the company’s strategic expansion initiatives.
Source: BSE
